TheraPPI Bioscience SAS

90% of cancer deaths are related to drug resistance which undercuts the efficacy of anti-cancer drugs like inhibitors of MAPK signaling, a pathway hyperactivated in 40% cancers. Another limitation of MAPK Inhibitors is their inability to cure rare diseases caused by MAPK-activating mutations.

To overcome these limitations, TheraPPI develop drugs inducing signal dysregulation instead of signal inhibition. Our two first programs target a MAPK protein interaction discovered by the founder team.